Aytu BioPharma
Open
$2.57
Prev. Close
$2.57
High
$2.57
Low
$2.57
Market Snapshot
$25.67M
-1.1
-0.97
$61.41M
83
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
emptyResult
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. The company is headquartered in Denver, Colorado and currently employs 82 full-time employees. The company went IPO on 2017-10-20. Its business is focused on the launch of EXXUA and its prescription pharmaceutical products sold primarily through third-party wholesalers and pharmacies and which primarily consists of two product portfolios. Its Attention Deficit Hyperactivity Disorder (ADHD) portfolio consists of Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) , Cotempla XR-ODT, and METADATE CD, which are CNS stimulants indicated for the treatment of ADHD in patients. Its Pediatric portfolio consists of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, Poly-Vi-Flor, and Tri-Vi-Flor. EXXUA is indicated to treat depressive disorder (MDD) in adults.
Recently from Cashu
Aytu BioPharma: Committed to Innovative Therapeutics and Advancing Patient Care Solutions
Aytu BioPharma's Strategic Focus on Innovative Therapeutics Aytu BioPharma, a biopharmaceutical company specializing in developing innovative therapeutics for unmet medical needs, continues to make st…
Aytu BioPharma's Earnings Report: Key Insights for Future Growth and Investor Sentiment
Aytu BioPharma's Upcoming Earnings: Key Indicators for Strategic Growth Aytu BioPharma prepares to release its quarterly earnings on November 13, 2025, a crucial event that stakeholders closely monito…
Aytu BioPharma Launches New Pediatric Medication, Enhancing Market Position and Patient Care
Aytu BioPharma Strengthens Its Position in the Pediatric Market with New Product Launch Aytu BioPharma, a key player in the pharmaceutical industry, is making significant strides in its commitment to…
Aytu BioPharma's Revenue Growth Driven by Innovative Product Launches and Strategic Partnerships
Aytu BioPharma Advances in Revenue Growth with New Product Launches Aytu BioPharma, a biopharmaceutical company focused on commercializing novel therapeutics for various medical conditions, continues…